FIA
NAGE

FNY Investment Advisers’s Niagen Bioscience NAGE Stock Holding History

FNY Investment Advisers’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-3,643
Closed -$16K – 1209
2019
Q2 		$16K Buy
+3,643
New +$15.5K ﹤0.01% 510

Other funds holding NAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

FNY Investment Advisers's NAGE Position: Q3 2019 in Review

FNY Investment Advisers sold out of Niagen Bioscience (NAGE) in Q3 2019, closing a stake of 3,643 shares — an estimated $16K sold.

FNY Investment Advisers first reported a position in NAGE in Q2 2019 and held it in 1 quarter. The position peaked at $16K in Q2 2019. 60 funds tracked by Wall St. Rank hold NAGE as of Q3 2019.

  • FNY Investment Advisers reported no remaining Niagen Bioscience position as of Q3 2019 after selling out during the quarter.
  • FNY Investment Advisers sold 3,643 Niagen Bioscience shares in Q3 2019, an estimated $16K.
  • FNY Investment Advisers first reported a position in Niagen Bioscience in Q2 2019 and held it in 1 quarter.
  • FNY Investment Advisers's Niagen Bioscience position peaked at $16K in Q2 2019.
  • 60 funds tracked by Wall St. Rank held Niagen Bioscience as of Q3 2019.

Based on FNY Investment Advisers's 13F filing for Q3 2019, filed 25 Oct 2019.